BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a ...
Yasir Gallero-Salas discusses quantifying alpha-synuclein spread and dopaminergic neuron loss in a model of Parkinson’s using ...
Nearly one million people in the U.S. are living with Parkinson’s disease (PD), and this number is expected to grow to 1.2 ...
Environmental factors like prolonged stress, chronic inflammation and toxic exposure could play a key role in triggering ...
New therapies that are less intrusive but more lasting than current interventions promise to arrest and even reverse neurodegeneration.
People with Parkinson's who have taken part in drum lessons have seen a "tangible difference" in their mobility, according to ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
When Denver artist Tim McKay was diagnosed with Parkinson’s disease last year, he made a quick decision: He would document ...
Scientists from the University of Rochester and other institutions have uncovered new evidence linking trichloroethylene (TCE ...
Backed by a $2.9 million R01 grant from the National Institutes of Health, Barrow Neurological Institute researchers are expanding their efforts to test a hypothesis that exposure to environmental ...
Wearable devices once seemed futuristic for Parkinson’s disease. Today, tools like activity trackers, tremor gloves, and ...